Algernon Pharmaceuticals Inc C.AGN

Phase 2 DMT Stroke Study Design Finalized

[SkywalkerofLuke]

Following encouraging results from AGN.c AGNPF’s Phase 1 study of DMT for stroke treatment, AGN is now advancing and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.

Worth noting that AGN is the world’s 1st company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries.

With ethics submission planned for later in Q3 and the study starting a short time after approval, I’m keeping an eye on AGN at their current price as the global stroke treatment market is expected to reach a value of $15B by the Year 2027 and AGN is at the forefront of innovative treatments.

https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/189/algernon-neuroscience-announces-40-patient-phase-2

[Whalewatcher1]

Nice post, but do you really think they can raise the $4-5m to run such trial with market cap below $2M and raise $200k to cover maybe a month of burn.   even if they figured out a way to raise the $, there's no real intellectual property in my opinion. They are taking off the shelf drug and giving to stroke patients.  I guess a last attempt to drum up interest from incestors

[Whalewatcher1]

This company needs new management. A reset on strategy, pick an indication and finally run a properly designed trial. Seemed they had positive trend data for chronic cough. Chris keeps using Bellus as a comparable. How about run the company like Bellus by bringing on board people on management team who know how to do real drug development, focus and do one trial right. Why is this so hard. Need a